Moclobemide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317117

CAS#: 71320-77-9

Description: Moclobemide is a reversible inhibitor of monoamine oxidase (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as the UK and Australia. Due to the lack of anticholinergic, cardiovascular, cognitive and psychomotor impairments, moclobemide is advantageous in the elderly as well as those with cardiovascular disease. (https://en.wikipedia.org/wiki/Moclobemide)


Chemical Structure

img
Moclobemide
CAS# 71320-77-9

Theoretical Analysis

MedKoo Cat#: 317117
Name: Moclobemide
CAS#: 71320-77-9
Chemical Formula: C13H17ClN2O2
Exact Mass: 268.09786
Molecular Weight: 268.74
Elemental Analysis: C, 58.10; H, 6.38; Cl, 13.19; N, 10.42; O, 11.91

Size Price Shipping out time Quantity
100mg USD 550 2 Weeks
200mg USD 950 2 Weeks
500mg USD 1650 2 Weeks
1g USD 2450 2 Weeks
2g USD 3850 2 Weeks
5g USD 5650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-27. Prices are subject to change without notice.

Moclobemide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: Ro11-1163; Ro 11-1163; Ro111163; Ro-111163; Ro 111163; Moclobemide; brand name: Amira; Aurorix; Clobemix; Depnil; Manerix.

IUPAC/Chemical Name: 4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide

InChi Key: YHXISWVBGDMDLQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)

SMILES Code: O=C(NCCN1CCOCC1)C2=CC=C(Cl)C=C2

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 268.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003 Spring;9(1):97-140. Review. PubMed PMID: 12595913.

2: Bonnet U. Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties. CNS Drug Rev. 2002 Fall;8(3):283-308. Review. PubMed PMID: 12353059.

3: Gumà M, Clemente F, Segura A, Costa J. [The serotoninergic syndrome: moclobemide and citalopram]. Med Clin (Barc). 1999 Nov 20;113(17):677-8. Review. Spanish. PubMed PMID: 10618787.

4: Amrein R, Martin JR, Cameron AM. Moclobemide in patients with dementia and depression. Adv Neurol. 1999;80:509-19. Review. PubMed PMID: 10410765.

5: Versiani M. Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. J Affect Disord. 1998 Dec;51(3):323-32. Review. PubMed PMID: 10333986.

6: Goldberg RJ. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Drugs Aging. 1997 Aug;11(2):119-31. Review. PubMed PMID: 9259175.

7: Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996 Sep;52(3):450-74. Review. Erratum in: Drugs 1996 Dec;52(6):869. PubMed PMID: 8875133.

8: Nutt D, Montgomery SA. Moclobemide in the treatment of social phobia. Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:77-82. Review. PubMed PMID: 8923114.

9: Angst J, Amrein R, Stabl M. Moclobemide: a paradigm of research in clinical psychopharmacology. Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:3-7. Review. PubMed PMID: 8923103.

10: Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet. 1995 Nov;29(5):292-332. Review. PubMed PMID: 8582117.

11: Hilton S, Jaber B, Ruch R. Moclobemide safety: monitoring a newly developed product in the 1990s. J Clin Psychopharmacol. 1995 Aug;15(4 Suppl 2):76S-83S. Review. PubMed PMID: 7593735.

12: Norman TR, Burrows GD. A risk-benefit assessment of moclobemide in the treatment of depressive disorders. Drug Saf. 1995 Jan;12(1):46-54. Review. PubMed PMID: 7741983.

13: Freeman H. Moclobemide. Lancet. 1993 Dec 18-25;342(8886-8887):1528-32. Review. PubMed PMID: 7902906.

14: Nair NP, Ahmed SK, Kin NM. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J Psychiatry Neurosci. 1993 Nov;18(5):214-25. Review. PubMed PMID: 7905288; PubMed Central PMCID: PMC1188542.

15: Tiller JW. Clinical overview on moclobemide. Prog Neuropsychopharmacol Biol Psychiatry. 1993 Sep;17(5):703-12. Review. PubMed PMID: 8255982.

16: Dingemanse J. An update of recent moclobemide interaction data. Int Clin Psychopharmacol. 1993 Jan;7(3-4):167-80. Review. PubMed PMID: 8468439.

17: Woggon B. The role of moclobemide in endogenous depression: a survey of recent data. Int Clin Psychopharmacol. 1993 Jan;7(3-4):137-9. Review. PubMed PMID: 8468434.

18: Silverstone T. Moclobemide--placebo-controlled trials. Int Clin Psychopharmacol. 1993 Jan;7(3-4):133-6. Review. PubMed PMID: 8468433.

19: Amrein R, Hetzel W, Stabl M, Schmid-Burgk W. RIMA--a new concept in the treatment of depression with moclobemide. Int Clin Psychopharmacol. 1993 Jan;7(3-4):123-32. Review. PubMed PMID: 8468432.

20: Haefely W, Burkard WP, Cesura A, Colzi A, Kettler R, Lorez HP, Martin JR, Moreau JL, Richards JG, Schaffner R, et al. Pharmacology of moclobemide. Clin Neuropharmacol. 1993;16 Suppl 2:S8-18. Review. PubMed PMID: 8313402.